magnetic resonance (MR) imaging disclosed a large, isodense high-density tumor of the left frontal lobe, apparently a recurrent tumor (Fig. 1 right) . In December 1991, the 9 ϫ 8-cm tumor was totally resected and the cut surface appeared to be partly hemorrhagic. Postoperative treatment for the malignant tumor was planned at that time, but the patient declined radiotherapy. Nine months after the surgery, the tumor recurred again. In November 1992, the tumor was subtotally resected. The patient received radiotherapy of 60 Gy to the tumor in a 5-week course beginning 45 days postoperatively. However, his aphasia progressed gradually. Computerized tomography and MR imaging revealed an increase in the size of the tumor. In January 1993, the tumor was again subtotally resected, followed by chemotherapy (methotrexate 5 mg administered twice locally). Two months after a final operation, performed in May 1993, the patient died at 35 years of age. An autopsy was performed but was limited to the brain.
Results

Histopathological Findings
Examined using light microscopy, the tumor extracted at the initial resection was primarily composed of an astroglial and ganglion cell component. Large polygonal ganglion cells were irregularly arranged in groups and binucleated ganglion cells were present ( Fig. 2A) . The ganglion cells were immunoreactive for neurofilament protein (NFP), synaptophysin (SY) (Fig. 2B) , and neuronspecific enolase (NSE). Astroglial components (including gemistocytes) stained positive for both glial fibrillary acidic protein (GFAP) (Fig. 2C ) and S-100 protein. In other areas, small immature cells were found that displayed considerably high cellularity, rare rosette formation, and small numbers of mitotic figures (Fig. 2D) . Immunohistochemically, a large number of these cells reacted positively to vimentin and some to GFAP.
In the tissue removed at the second resection, most tumors were uniformly composed of small cells with round-to-oval nuclei and scanty cytoplasm (Fig. 2E) , although differentiated ganglioglioma were present on the surfaces of the tumors. In areas of small neoplastic cells, mitoses were often present. Areas of hemorrhage and necrosis were seen, but there was no pseudopalisading around necrotic areas, cellular pleomorphism, or endothelial proliferation. Reticulin fibers were sparse and surrounded small neoplastic cells. The small neoplastic cells displayed positive immunoreactivity to antivimentin but not to anti-NFP, -SY, -desmin, or anti-smooth muscle actin. The GFAP immunoreactivity was equivocal on routine immunostaining, but definite on protease-treated paraffin sections (Fig. 2F) .
In the specimens obtained at the third, fourth, and fifth resections, there were no areas of differentiated ganglioglioma. The histology and immunophenotype of the tumor cells of those resections were similar to those of the small neoplastic cells observed at the second resection. In tissue from the third resection, spindle-shaped cells with fascicular patterns were noted (Fig. 2G ). Some tumor cells had eccentric, pale areas in their cytoplasms (Fig. 2H ). In the specimen from the fourth resection, mitoses were numerous (19 in 10 high-power fields). The brain autopsy disclosed swelling, herniation, and recurrent tumors with meningeal dissemination of the small neoplastic cells.
No tumor cells displayed any detectable immunoreactivity for p53 protein.
Proliferative Markers
The results of proliferating activity analyses for immature tumor cells are summarized in Table 1 . Nuclear labeling with Ki-67 or MIB-1 antibodies was observed in immature neoplastic cells, but not in differentiated ganglion cells.
Electron Microscopy Findings
Electron microscopy evaluation of tissue samples obtained at the second and third resections revealed small tumor cells embedded in considerably abundant, fuzzy matrices, without surrounding basal lamina or attachment devices (Fig. 3A) . The tumor cells contained mitochondria and numerous rough endoplasmic reticula with marked dilation and frequent concentric lamination in their cytoplasm. They had short cell processes which included scattered intermediate filaments. Cilia were rarely observed in the tumor cells (Fig. 3B) . No neurosecretory granules were identified. * Abbreviations: AgNORs = silver nucleolar organizer regions; hpfs = high-power fields; NE = not examined.
Western Blot Analysis
Frozen tumor tissue specimens obtained from the fourth operation were prepared for immunoblotting with anti-GFAP antibody. The analysis revealed a weak band at approximately 50 kD in the fractions obtained from cytoskeletal preparations from the fourth resection (Fig. 4) .
Discussion
Histologically, gangliogliomas are defined as neoplasms composed of an intimate admixture of neoplastic astrocytes and atypical ganglion cells. 20 Immunohistochemical analysis using neuronal (SY, NFP, NSE) and glial (GFAP) markers has been shown to be useful in the diagnosis of ganglioglioma. 6, 17 In the initial tumor of the present case there was no doubt about the presence of ganglioglioma. According to the 1993 World Health Organization (WHO) classification, 14 gangliogliomas are graded as I or II and anaplastic ganglioglioma as Grade III. Histological criteria for the grading of these tumors are yet to be defined. However, ganglioglioma containing areas of pronounced hypercellularity, vascular proliferation, necrosis, and many mitotic figures are conventionally classified as anaplastic ganglioglioma. 14, 18, 21, 22 The glial component of our patient's initial tumor was partly hypercellular and contained a few mitotic figures. Therefore, it was designated as Grade I with small areas corresponding to Grade III. In previous studies of large series of gangliogliomas, 21 ,22 the frequencies of Grades I, II, and III were approximately 85%, 10%, and 5%, respectively. Thus, the primary tumor described in the present case was a very rare type of lesion.
The first recurrent tumor had a large area of small, poorly differentiated cells as well as a small area of typical ganglioglioma. Clinical and radiological data, as well as pathological findings, suggest that the recurrent tumor could have arisen from a preexisting ganglioglioma and could be diagnosed as recurrent anaplastic ganglioglioma. At the level of light microscopy, these anaplastic lesions appeared to be composed of small undifferentiated cells; these cells became the single neoplastic components in subsequent recurrent tumors. Anaplastic changes and malignant transformations of gangliogliomas are exceptional and for the most part are restricted to the glial component in reported cases. 1, 2, 4, [8] [9] [10] [11] 20 Thus, anaplastic lesions of gangliogliomas correspond to glioblastoma or anaplastic glioma. However, our patient's tumor did not show features typically seen in glioblastoma. On conventionally stained histological slides, the recurrent tumors showed no evidence of glial differentiation and might be difficult to distinguish from primitive neuroectodermal tumor or unclassified sarcoma. Immunohistochemically, the tumor cells revealed a definite immunoreactivity for GFAP only when the formalin-fixed, paraffin-embedded tissue sections were pretreated with protease. Western blot analysis performed on a sample from the fourth resection detected weak expression of GFAP molecules in the tumor. These findings suggest that recurrent anaplastic cells might contain small quantities of GFAP. Under the electron microscope, most of the recurrent anaplastic tumor cells showed undifferentiated features, but some displayed glial features with intermediate filaments, cilia, and concentric laminations of the endoplasmic reticulum. 12 Combining these analyses, glial (astrocytic) differentiation was partly identified in the recurrent anaplastic tumors.
In our patient's recurrent tumors, a high level of proliferative activity was signaled by frequent mitotic figures on routine histological examinations. We used MIB-1 and Ki-67 labeling and the silver nucleolar organizer region (AgNOR) method to analyze proliferative capacity quantitatively. The monoclonal antibody MIB-1 recognizes the same or a very similar epitope as Ki-67, 13 although the immunohistochemical technique for labeling each of these antigens is different and the MIB-1 proliferating cell indices (PCIs) sometimes correlate poorly with the Ki-67 PCIs. The Ki-67 PCIs ranged from 0.6% to 3.2% (mean 1.7%) and from 1.3% to 12.4% (mean 6.2%) for astrocytomas and glioblastomas, respectively. 3 Thus, the MIB-1 and Ki-67 PCIs of our recurrent tumor were consistent with those of glioblastoma. In addition, the AgNOR impregnation showed moderate-to-high AgNOR counts compared to those in the literature. 16 A high proliferative capacity of the recurrent tumor appears to be consistent with the progression of the present case. It is noteworthy that the Ki-67 and MIB-1 PCIs and the AgNOR counts all decreased in the third recurrent tumor. This might be due to the effect of radiation therapy, which was used after the operation on the second recurrence. However, intratumoral differences in indices of tumor cell proliferation should be considered, because regional differences in the expression of the Ki-67 protein and AgNOR counts in glioblastoma have been suggested by Onda, et al. 19 The proliferative potential of the initial tumor in this case was measured using MIB-1 monoclonal antibody because only paraffin sections were available. Wolf and colleagues 21 showed that the labeling indices for Ki-67 were less than 10% in all gangliogliomas (61 cases), except for a single case of a Grade II ganglioglioma, and that 74% of gangliogliomas had a Ki-67 PCI of less than 1%. In our patient's initial tumor, MIB-1 was observed in the nuclei of less differentiated glial cells with moderate cellularity and rare mitotic figures; the MIB-1 PCI was 7%. Thus the proliferative capacity of the initial tumor in the present case was considered high for gangliogliomas. The high MIB-1 PCI might be related to the development of tumor A. Sasaki, et al. recurrence. A previous study 21 showed a significant correlation between WHO grading of gangliogliomas and Ki-67 indices and that four of six patients with WHO Grade II tumors developed tumor recurrences or tumor progression. Therefore, the present case supports the use of Ki-67 or MIB-1 in specifying the grade and evaluating the prognosis.
Currently, postoperative radiation therapy is recommended only if there is tumor progression or histological evidence of anaplastic ganglioglioma. The present case indicates that postoperative radiation might be necessary for the treatment of Grade III lesions and that careful follow up over a longer period (Ͼ 5 years) could be recommended.
Conclusions
A patient developed ganglioglioma with mild atypia in the cerebral hemisphere and underwent total tumor resection. Six and one-half years later, recurrences began and eventually led to a fatal outcome. The recurrent tumors had an unusual histology: they were composed of undifferentiated cells. After extensive pathological study, these tumors were diagnosed as malignant glioma with slightly astrocytic differentiation. This case suggests that ganglioglioma with mild atypia and high MIB-1 labeling can recur more than 5 years after total resection and that careful histological examinations with proliferative markers for the primary tumor should be applied to the management of ganglioglioma.
